Amy Webb
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Amy Webb has a total of 122 co-authors. Here are the top co-authors by number of shared publications:
- Allison DePersia
NorthShore University HealthSystem 6
10 shared publications - Amanda Ewart Toland
Department of Cancer Biology and Genetics, Comprehensive Cancer Center, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, USA
10 shared publications - Ava Willoughby
The Ohio State University Wexner Medical Center 3 Columbus, Ohio
10 shared publications - Darcy Thull
University of Pittsburgh 10 Pittsburgh, Pennsylvania
10 shared publications - Doreen M. Agnese
The Ohio State University
10 shared publications - Erika L. Spaeth
Phenogen Sciences Inc, Charlotte, North Carolina, United States of America
10 shared publications
Latest Publications
- 29 October 2026
- Published by Wolters Kluwer Health in Circulation Research
BAHCC1 Drives Smooth Muscle Plasticity and Neointima via Epigenetic Repression
BACKGROUND: Vascular smooth muscle cell (SMC) phenotypic plasticity drives neointimal hyperplasia (IH) and contributes to atherosclerosis. Epigenetic mechanisms have been implicated in SMC plasticity, but the roles of epigenetic reader proteins are poorly understood. BAHCC1 (bromo adjacent homology domain coiled-coil 1) is a newly identified reader of the gene-repression histone mark histone-3 lysine 27 trimethylation (H3K27me3). Its role in vascular remodeling is unknown. METHODS: We investigated BAHCC1 in human restenotic and atherosclerotic arteries and in rat and mouse arterial injury models using BAHCC1 silencing, SMC-specific deletion, and an H3K27me3-binding-deficient knock-in mutation. Mechanistic studies in human aortic SMCs integrated transcriptomic and epigenomic profiling, protein-interaction assays, and single-guide RNA-dCas9-based epigenetic editing. RESULTS: BAHCC1 was upregulated in human restenotic and atherosclerotic arteries and rat arteries with IH. While BAHCC1 silenc ing reduced IH in balloon-injured rat arteries, SMC-specific BAHCC1 deletion and the H3K27me3-binding-deficient mutation (BAHCC1 Y2537A ) attenuated IH in wire-injured mouse arteries. In human SMCs, mitogen induced BAHCC1 expression through nuclear factor Y subunit-α, promoting BAHCC1-dependent dedifferentiation. Integrated transcriptomics and epigenomics identified LMO7 (LIM domain only 7), an IH suppressor, as a key BAHCC1-repressed target. BAHCC1 occupancy at LMO7 required BAHCC1-H3K27me3 interaction, and LMO7 -targeted H3K27me3 enrichment through epigenetic editing repressed its expression in a BAHCC1-dependent manner. Furthermore, BAHCC1 associated with SAP30 and RBBP4/7 to form a corepressor complex. Functionally, LMO7 silencing reversed the effects of BAHCC1 knockdown on human SMC phenotype and exacerbated IH in BAHCC1 Y2537A mice. Human genetic analyses further identified BAHCC1 variants associated with cardiovascular phenotypes and BAHCC1 expression. CONCLUSIONS: BAHCC1 is a previously unrecognized epigenetic driver of vascular remodeling. By reading H3K27me3 and recruiting corepressors to repress gene expression, BAHCC1 promotes pathological SMC phenotypic transition and IH, highlighting the BAHCC1 pathway as a potential therapeutic target for IH-associated vascular disease.
- 29 October 2026
- Published by Wolters Kluwer Health in Circulation Research
BAHCC1 Drives Smooth Muscle Plasticity and Neointima via Epigenetic Repression
BACKGROUND: Vascular smooth muscle cell (SMC) phenotypic plasticity drives neointimal hyperplasia (IH) and contributes to atherosclerosis. Epigenetic mechanisms have been implicated in SMC plasticity, but the roles of epigenetic reader proteins are poorly understood. BAHCC1 (bromo adjacent homology domain coiled-coil 1) is a newly identified reader of the gene-repression histone mark histone-3 lysine 27 trimethylation (H3K27me3). Its role in vascular remodeling is unknown. METHODS: We investigated BAHCC1 in human restenotic and atherosclerotic arteries and in rat and mouse arterial injury models using BAHCC1 silencing, SMC-specific deletion, and an H3K27me3-binding-deficient knock-in mutation. Mechanistic studies in human aortic SMCs integrated transcriptomic and epigenomic profiling, protein-interaction assays, and single-guide RNA-dCas9-based epigenetic editing. RESULTS: BAHCC1 was upregulated in human restenotic and atherosclerotic arteries and rat arteries with IH. While BAHCC1 silenc ing reduced IH in balloon-injured rat arteries, SMC-specific BAHCC1 deletion and the H3K27me3-binding-deficient mutation (BAHCC1 Y2537A ) attenuated IH in wire-injured mouse arteries. In human SMCs, mitogen induced BAHCC1 expression through nuclear factor Y subunit-α, promoting BAHCC1-dependent dedifferentiation. Integrated transcriptomics and epigenomics identified LMO7 (LIM domain only 7), an IH suppressor, as a key BAHCC1-repressed target. BAHCC1 occupancy at LMO7 required BAHCC1-H3K27me3 interaction, and LMO7 -targeted H3K27me3 enrichment through epigenetic editing repressed its expression in a BAHCC1-dependent manner. Furthermore, BAHCC1 associated with SAP30 and RBBP4/7 to form a corepressor complex. Functionally, LMO7 silencing reversed the effects of BAHCC1 knockdown on human SMC phenotype and exacerbated IH in BAHCC1 Y2537A mice. Human genetic analyses further identified BAHCC1 variants associated with cardiovascular phenotypes and BAHCC1 expression. CONCLUSIONS: BAHCC1 is a previously unrecognized epigenetic driver of vascular remodeling. By reading H3K27me3 and recruiting corepressors to repress gene expression, BAHCC1 promotes pathological SMC phenotypic transition and IH, highlighting the BAHCC1 pathway as a potential therapeutic target for IH-associated vascular disease.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Figure S1: Enhanced Risk Estimate Participant Reports.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Figure S1: Enhanced Risk Estimate Participant Reports.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Materials S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Materials S1. Baseline and Follow-up Survey Questions.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Materials S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Materials S1. Baseline and Follow-up Survey Questions.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Materials S2 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Materials S2. Survey Scoring.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Materials S2 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Materials S2. Survey Scoring.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S2 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S2. SNVs and weights used for BRCA2 88-SNV Breast PRS model.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S2 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S2. SNVs and weights used for BRCA2 88-SNV Breast PRS model.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S3 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S3. SNVs and weights used for BRCA1 Ovarian PRS model.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S3 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S3. SNVs and weights used for BRCA1 Ovarian PRS model.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S1. SNVs and weights used for BRCA1 ER- 53-SNV Breast PRS Model.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S1 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S1. SNVs and weights used for BRCA1 ER- 53-SNV Breast PRS Model.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S6 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S6. Comparison of GRE and 313-SNV breast cancer risks.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S6 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S6. Comparison of GRE and 313-SNV breast cancer risks.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S4 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S4. SNVs and weights used for BRCA2 Ovarian PRS model.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S4 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S4. SNVs and weights used for BRCA2 Ovarian PRS model.
- Open Access
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table S5 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S5. Representativeness of Study Participants.
- 1 September 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table S5 from The Clinical Application of Refined Risk Estimates Study in BRCA1 and BRCA2 Pathogenic Variant Carriers: A Randomized Controlled Trial
Supplemental Table S5. Representativeness of Study Participants.